AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET

Company Participants

Tryn Stimart - Chief Legal and Compliance Officer

Dr. Carl Hansen - President and CEO

Andrew Booth - CFO

Conference Call Participants

Tiago Fauth - Credit Suisse

Puneet Souda - SVB Securities

Stephen Willey - Stifel

Gary Nachman - BMO Capital Markets

Do Kim - Piper Sandler

Antonia Borovina - Bloom Burton

Operator

Good afternoon and welcome to AbCellera Second Quarter 2022 Business Update and Conference Call. My name is Libya and I'll facilitate the audio portion of today's indirect broadcast. [Operator instructions]

At this time, I would like to turn the conference over to Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. Mr. Stimart, please proceed.

Tryn Stimart

Thank you. Good afternoon and welcome to AbCellera's second quarter 2022 business update. We are pleased to have you with us today where we will discuss the results announced in our press release issued after the market closed today which you can find on our Investor Relations website.

With me on the call are Dr. Carl Hansen, AbCellera's Chief Executive Officer and President; and Andrew Booth, AbCellera's Chief Financial Officer. The webcast portion of this call contains a slide presentation that we will refer to during the call. If you're following along on the phone and wish to access the slide portion of this presentation, you may do so on the Investor Relations section of our website.

For those who have accessed the streaming portion of the webcast, please be aware that there may be a delay and that you will not be able to post questions via the web. This presentation may contain forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements are based on management's current expectations and are subject to certain risks and uncertainties. Please review our SEC filings for risk factors that could impact our future performance. Our presentation and SEC filings are available on our Investor Relations website. Note that all dollars referred to on our call today are U.S. dollars.

Now, I am pleased to turn the call over to Carl Hansen.

Dr. Carl Hansen

Thanks Tryn and thank you, everyone for joining us today. It's my pleasure to provide an update on our business for the second quarter of 2022. AbCellera is on rock solid footing. Despite what has been a challenging time for biotech, we believe the current marketing environment is a strong tailwind for our business. We ended the quarter with over $1 billion in cash, cash equivalents and marketable securities, and we are fully funded to continue executing on our strategy and building our business.